Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Peer Reviewed
See detailOnce-a-day administration of amikacin in neonates: clinical evidence of the validity of a pharmacokinetic according to the gestational age
Battisti, Oreste ULg; Wallemacq P; Langhendries JP

in Early Human Development (1994), 38

Detailed reference viewed: 12 (0 ULg)
Peer Reviewed
See detailthe once-daily concept of aminoglycoside administration adapted in neonatalogy
Battisti, Oreste ULg

in Pediatric Research (1998), 2

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailOnce-monthly and daily oral ibandronate are at least as effective in improving proximal femur BMD in postmenopausal osteoporosis: 12-month data from MOBILE
Reginster, Jean-Yves ULg; Lorenc, R.; Stepan, J. J. et al

in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 93

Detailed reference viewed: 2 (1 ULg)
Full Text
Peer Reviewed
See detailOnce-monthly dosing of oral ibandronate is highly efficacious: 2-year results from mobile
Reginster, Jean-Yves ULg; Stakkestad, J. A.; Lorenc, R. et al

in Osteoporosis International (2006, March), 17(Suppl.1), 64-65

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailOnce-monthly oral ibandronate (Boniva) dosing is highly efficacious in postmenopausal osteoporosis: 2-year results from MOBILE
Silverman, Stuart; Greenwald, M.; Hawker, G. et al

in Arthritis and Rheumatism (2005, September), 52(number 9 (suppl.)), 735-736

Detailed reference viewed: 34 (0 ULg)
Full Text
Peer Reviewed
See detailOnce-monthly oral ibandronate a new bisphosphonate dosing concept
Reginster, Jean-Yves ULg; Miller, P.; Delmas, P. et al

in Calcified Tissue International (2004), 74(S1), 85

Detailed reference viewed: 2 (2 ULg)
Full Text
Peer Reviewed
See detailOnce-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Miller, Paul D; Epstein, Sol; Sedarati, Farhad et al

in Current Medical Research & Opinion (2008), 24(1), 207-13

OBJECTIVE: Oral ibandronate 150 mg is the first bisphosphonate approved for once-monthly treatment of postmenopausal osteoporosis. To investigate whether once-monthly ibandronate 150 mg increases lumbar ... [more ▼]

OBJECTIVE: Oral ibandronate 150 mg is the first bisphosphonate approved for once-monthly treatment of postmenopausal osteoporosis. To investigate whether once-monthly ibandronate 150 mg increases lumbar spine and total hip bone mineral density (BMD) to the same degree as weekly alendronate 70 mg. RESEARCH DESIGN AND METHODS: This was a 12-month, randomised, multinational, multicentre, double-blind, double-dummy, parallel-group, non-inferiority trial, conducted in 65 centres in North America, Latin America, Europe and South Africa. The study included postmenopausal women, mean lumbar spine (L2-L4) BMD T-score < -2.5 and > or = -5.0. Patients received either ibandronate 150 mg once monthly or alendronate 70 mg once weekly. MAIN OUTCOME MEASURES: Co-primary efficacy endpoints were 12-month change (%) from baseline in mean lumbar spine and total hip BMD. Changes (%) from baseline in trochanter and femoral neck BMD were also evaluated. Adverse events were monitored throughout. Once-monthly ibandronate was considered non-inferior to weekly alendronate if the lower boundary of the one-sided 97.5% confidence interval (CI) (or two-sided 95% CI) was > or = -1.41% for lumbar spine and > or = -0.87% for total hip. RESULTS: Mean relative 12-month changes were 5.1% and 5.8% (95% CI for difference, -1.13, -0.23) in lumbar spine and 2.9% and 3.0% (95% CI for difference, -0.38, 0.18) in total hip BMD with once-monthly ibandronate and weekly alendronate, respectively; meeting the non-inferiority criteria at both sites. Gains in trochanter and femoral neck BMD were similar with both treatments. Both regimens were well tolerated. TRIAL REGISTRATION: The MOTION study is registered with the International Federation of Pharmaceutical Manufacturers and Associations trial portal, under the ID number MM17385. CONCLUSIONS: Once-monthly ibandronate was shown to be clinically comparable to weekly alendronate at increasing BMD after 12 months in both the lumbar spine and total hip. [less ▲]

Detailed reference viewed: 52 (2 ULg)
Full Text
Peer Reviewed
See detailOnce-weekly alendronate produces a greater decrease in bone resorption than daily risedronate
Adami, Silvio; Felsenberg, D.; Hosking, D. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 14-15

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailOnce-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production.
Cazzola, Mario; Beguin, Yves ULg; Kloczko, Janusz et al

in British Journal of Haematology (2003), 122(3), 386-93

Epoetin beta, three-times weekly (t.i.w.), is effective in reversing anaemia in lymphoproliferative disorders. The current study investigated whether an epoetin beta dose of 30,000 IU given subcutaneously ... [more ▼]

Epoetin beta, three-times weekly (t.i.w.), is effective in reversing anaemia in lymphoproliferative disorders. The current study investigated whether an epoetin beta dose of 30,000 IU given subcutaneously once weekly (q.w.) was at least as effective as 10,000 t.i.w. administration in anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin (Epo) production. Overall, 241 anaemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma or chronic lymphocytic leukaemia, all with serum Epo values </= 100 mU/ml, were randomized to receive the q.w. (n = 119) or t.i.w. (n = 122) regimen for 16 weeks. The primary efficacy criterion, i.e. the time-adjusted area under the haemoglobin-time curve from weeks 5-16, was comparable between the q.w. and t.i.w. groups [difference = - 0.20 g/dl (90% confidence interval - 0.52-0.11)]. Moreover, response rates were high and similar in both arms (72%vs 75%, q.w. and t.i.w. groups respectively). Baseline serum Epo was predictive of response: the lower serum Epo, the higher the likelihood of response (P = 0.002). Thus, epoetin beta administered q.w. is an effective and convenient treatment for anaemia in patients with lymphoproliferative disorders. Tailoring this treatment modality to subjects with defective endogenous Epo production represents a rational use of epoetin from both a medical and a community perspective. [less ▲]

Detailed reference viewed: 26 (0 ULg)
Full Text
Peer Reviewed
See detailOncogène et traitement du cancer
Burny, A.; Cleuter, Y.; Couez, D. et al

in Revue Médicale de Bruxelles (1985)

Detailed reference viewed: 4 (1 ULg)
Full Text
Peer Reviewed
See detailOncogene-induced senescence relayed by an interleukin-dependent inflammatory network.
Kuilman, Thomas; Michaloglou, Chrysiis; Vredeveld, Liesbeth C. W. et al

in Cell (2008), 133(6), 1019-1031

Oncogene-induced cellular senescence (OIS) is emerging as a potent cancer-protective response to oncogenic events, serving to eliminate early neoplastic cells from the proliferative pool. Using combined ... [more ▼]

Oncogene-induced cellular senescence (OIS) is emerging as a potent cancer-protective response to oncogenic events, serving to eliminate early neoplastic cells from the proliferative pool. Using combined genetic and bioinformatic analysis, we find that OIS is linked specifically to the activation of an inflammatory transcriptome. Induced genes included the pleiotropic cytokine interleukin-6 (IL-6), which upon secretion by senescent cells acted mitogenically in a paracrine fashion. Unexpectedly, IL-6 was also required for the execution of OIS, but in a cell-autonomous mode. Its depletion caused the inflammatory network to collapse and abolished senescence entry and maintenance. Furthermore, we demonstrate that the transcription factor C/EBPbeta cooperates with IL-6 to amplify the activation of the inflammatory network, including IL-8. In human colon adenomas, IL-8 specifically colocalized with arrested, p16(INK4A)-positive epithelium. We propose a model in which the context-dependent cytostatic and promitogenic functions of specific interleukins contribute to connect senescence with an inflammatory phenotype and cancer. [less ▲]

Detailed reference viewed: 9 (1 ULg)
Peer Reviewed
See detailLes oncogènes dans les cancers du sein.
Gol-Winkler, Rose; Pasleau, Françoise ULg; Dijkmans, Huguette

Conference (1990)

Detailed reference viewed: 50 (2 ULg)
See detailOncogenic human papillomavirus could directly interact with Natural Killer cells
Renoux, Virginie; Bastin, Renaud ULg; Boniver, Jacques ULg et al

Poster (2012, June 22)

Detailed reference viewed: 5 (2 ULg)
Full Text
See detailOncogenic human papillomavirus could directly interact with natural killer cells
Renoux, V; Bastin, R; Langers, I et al

Poster (2012)

Detailed reference viewed: 13 (0 ULg)
See detailOncogenic human papillomavirus could directly interact with Natural Killer cells
Renoux, Virginie; Bastin, Renaud ULg; Boniver, Jacques ULg et al

Poster (2012, May 04)

Detailed reference viewed: 8 (4 ULg)
See detailOncogenic human papillomavirus could directly interact with Natural Killer cells
Renoux, Virginie; Bastin, Renaud ULg; Boniver, Jacques ULg et al

Poster (2012, December 10)

Detailed reference viewed: 18 (13 ULg)
Peer Reviewed
See detailOncogenic potential of Tax requires phosphorylation on serines 106 et 293.
Willems, Luc ULg; Grimonpont, Catherine; Kerkhofs, Pierre et al

in Virus Research (1997), 47(2 -Special Issue), 121-122

Detailed reference viewed: 3 (0 ULg)
See detailOncogenome sequencing: is it sustainable?
Massart, Sébastien ULg; Alexandre, L.

Conference (2012, June)

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailOncological Applications of Positron Emission Tomography with Fluorine-18 Fluorodeoxyglucose
Rigo, Pierre ULg; Paulus, Patrick; Kaschten, Bruno et al

in European Journal of Nuclear Medicine (1996), 23(12), 1641-74

Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical ... [more ▼]

Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and follow-up. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved. [less ▲]

Detailed reference viewed: 39 (1 ULg)